Retatrutide vs. Tirzepatide vs. Semaglutide: Phase 3 Efficacy and Safety Data Compared
With TRIUMPH-1 reporting on May 21, 2026, we now have Phase 3 data for three generations of incretin therapy: semaglutide (~17%), tirzepatide (~23%), retatrutide (~28%). Complete data comparison with methodology caveats.
With TRIUMPH-1 reporting on May 21, 2026, we now have Phase 3 efficacy data for three generations of incretin-based obesity therapeutics. This article compiles the published and topline trial data into a single comparative reference, noting the limitations of cross-trial comparison and where direct head-to-head data is expected.
The Three Generations
| Drug | Mechanism | Manufacturer | Status |
|---|---|---|---|
| Semaglutide 2.4 mg | GLP-1 mono-agonist | Novo Nordisk | FDA-approved (Wegovy) |
| Tirzepatide 15 mg | GLP-1/GIP dual agonist | Eli Lilly | FDA-approved (Zepbound) |
| Retatrutide 12 mg | GLP-1/GIP/glucagon triple agonist | Eli Lilly | Investigational — Phase 3 |
Weight Loss Efficacy: Phase 3 Data
Primary efficacy endpoint comparison (non-diabetic obesity populations, max dose arms):
| Metric | Semaglutide (STEP-1) | Tirzepatide (SURMOUNT-1) | Retatrutide (TRIUMPH-1) |
|---|---|---|---|
| Trial duration | 68 weeks | 72 weeks | 80 weeks |
| Participants (total) | 1,961 | 2,539 | 2,339 |
| Mean weight loss (%) | ~16.9% | ~22.5% | 28.3% |
| Mean weight loss (lbs) | ~33.7 lbs | ~52.0 lbs | 70.3 lbs |
| ≥20% responders | ~32% | ~57% | Data pending |
| ≥30% responders | Not reported | ~36% | 45.3% |
| BMI <30 achieved | Not reported | Not reported | 65.3% |
Critical caveat: These are cross-trial comparisons. Different trial populations, baseline BMIs, run-in periods, lifestyle intervention protocols, and durations make direct numerical comparison imprecise. The only valid head-to-head data will come from TRIUMPH-5, which has not yet reported.
The Glucagon Receptor Difference
The consistent ~5–6 percentage point increment at each receptor expansion — from mono (16.9%) to dual (22.5%) to triple (28.3%) — suggests each mechanism contributes additive, non-redundant efficacy:
- GLP-1 receptor: Appetite suppression, delayed gastric emptying, central satiety signaling. Primary mechanism for all three drugs.
- GIP receptor (added in tirzepatide): Enhanced insulin sensitivity, additional appetite regulation, possibly improved tolerability. Incremental ~5.6 pp weight loss.
- Glucagon receptor (added in retatrutide): Increased energy expenditure, enhanced hepatic lipid oxidation, thermogenesis. Incremental ~5.8 pp weight loss.
The glucagon component is the mechanistic differentiator. Glucagon receptor activation increases basal energy expenditure and drives hepatic fat clearance — pathways that are not engaged by GLP-1 or GIP agonism alone. This may explain why retatrutide shows particularly strong signals on waist circumference (visceral fat) and liver fat markers.
Safety and Tolerability Comparison
All three drugs share the same class-effect GI adverse event profile (nausea, vomiting, diarrhea, constipation). The key differentiators:
| Safety Metric | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| GI AE rate | ~44% | ~51% | ~55–60% (est.) |
| Discontinuation (AE) | ~7% | ~5–7% | ~18% (TRIUMPH-4, 12 mg) |
| Dysesthesia | Not reported | Not reported | 20.9% (TRIUMPH-4) |
| Pancreatitis signal | Rare | Rare | Pending full data |
The elevated discontinuation rate with retatrutide — approximately 2.5× higher than semaglutide or tirzepatide — is the primary safety concern. Dysesthesia (abnormal skin tingling/burning sensation) is unique to retatrutide and appears to be glucagon-receptor mediated. Most cases occur during dose escalation and diminish at maintenance, but persistence at full dose contributed to the higher dropout rate.
Cardiometabolic Outcomes
Semaglutide currently holds the strongest cardiovascular evidence base, with the SELECT trial demonstrating a 20% reduction in MACE events. Tirzepatide's CVOT (SURPASS-CVOT) data is pending. Retatrutide's TRIUMPH-3 (established CVD population) has not yet reported.
| Outcome | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| MACE reduction | 20% (SELECT) | Pending | Pending (TRIUMPH-3) |
| Kidney disease | 24% progression reduction (FLOW) | Pending | Pending |
| Sleep apnea | Post-hoc only | FDA-approved indication | Pending |
| Knee OA pain | Not studied | Not studied | 75.8% reduction (TRIUMPH-4) |
| Waist circumference | ~13 cm (STEP) | ~18 cm (SURMOUNT) | 24.1 cm (TRIUMPH-4) |
What's Still Missing
- Head-to-head Phase 3 data: TRIUMPH-5 is the active-comparator trial. Until it reports, all three-way comparisons are indirect.
- Long-term safety (>2 years): None of these agents have published 3+ year safety data from randomized trials.
- Retatrutide TRIUMPH-1 detailed data: Topline results only; full dataset with subgroup analyses expected at ADA June 2026.
- Real-world effectiveness: Phase 3 trial populations are not representative of real-world patients. Discontinuation rates in clinical practice are typically higher than in trials.
- Cost-effectiveness data: No published ICER or QALY analyses comparing all three agents at their trial-demonstrated efficacy levels.
The Bottom Line
Three generations of incretin therapy now have Phase 3 efficacy data: semaglutide (~17%), tirzepatide (~23%), retatrutide (~28%). Each additional receptor target adds approximately 5–6 percentage points of weight loss, but also incrementally increases the GI adverse event burden and discontinuation rate. Retatrutide's 28.3% signal is clinically significant and positions the triple-agonist mechanism as the most effective pharmaceutical weight-loss intervention tested to date. The tolerability trade-off — particularly the 18% discontinuation rate and novel dysesthesia signal — will be the defining regulatory and clinical question. TRIUMPH-5 head-to-head data and detailed TRIUMPH-1 safety data (ADA June 2026) are the next critical data points.
Sources
- Eli Lilly. "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial." May 21, 2026.
- Jastreboff AM et al. "Triple–hormone-receptor agonist retatrutide for obesity — a Phase 2 trial." N Engl J Med. 2023;389:514-526.
- Wilding JPH et al. "Once-weekly semaglutide in adults with overweight or obesity." STEP-1. N Engl J Med. 2021;384:989-1002.
- Jastreboff AM et al. "Tirzepatide once weekly for the treatment of obesity." SURMOUNT-1. N Engl J Med. 2022;387:327-340.
- Eli Lilly. TRIUMPH-4 topline results. December 2025.
- Lincoff AM et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." SELECT. N Engl J Med. 2023.
- Perkovic V et al. "Effects of Semaglutide on Chronic Kidney Disease." FLOW. N Engl J Med. 2024.
- TCTMD. "Retatrutide Achieves Large Weight Decreases in Patients Without Diabetes: TRIUMPH-1." May 22, 2026.
- AJMC. "Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial." May 21, 2026.
- Pharmacy Times. "Retatrutide Delivers Bariatric-Level Weight Loss in Pivotal Phase 3 TRIUMPH-1 Trial." May 22, 2026.